Xtant Medical Raises FY23 Revenue Guidance To $88M-$91M, Compared To Prior Guidance Of $75M-$77M And Consensus Of $77.00M
Portfolio Pulse from Benzinga Newsdesk
Xtant Medical has increased its FY23 revenue guidance to $88M-$91M, up from the previous guidance of $75M-$77M and surpassing the consensus of $77.00M.
November 09, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xtant Medical's raised FY23 revenue guidance could positively impact its stock price in the short term.
Xtant Medical has raised its FY23 revenue guidance significantly above the previous estimates and consensus. This indicates strong business performance and future growth potential, which could lead to increased investor confidence and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100